Lilly Oncology on Canvas Invites Entries

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

Eli Lilly and Company and the National Coalition for Cancer Survivorship have issued a call for entries for the 2006 Lilly Oncology on Canvas: Expressions of a Cancer Journey International Art Competition and Exhibition.

INDIANAPOLIS—Eli Lilly and Company and the National Coalition for Cancer Survivorship have issued a call for entries for the 2006 Lilly Oncology on Canvas: Expressions of a Cancer Journey International Art Competition and Exhibition. The competition invites people diagnosed with any type of cancer, their families and friends, cancer advocates, and health care providers, as well as artists and art students, to express, through art and narrative, their own cancer journeys. Art entries will be accepted through July 30, 2006, in the following media: oil, watercolor, acrylic, pastel, photography, and other one-dimensional art. Winners of the 2004 competition can be viewed at www.lilly.com. For additional contest details and to obtain a registration form, please call 1-800-734-4131 or contact Anita Chernewski, art director, at achernewski@cprworldwideusa.com.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.